Business Description
Chemomab Therapeutics is an Israeli medical research company working to develop new treatments for serious conditions that cause inflammation and scarring in the body's tissues and organs. Its primary drug, nebokitug, targets a specific protein called CCL24, which plays a key role in driving these harmful processes. The company has tested nebokitug in two mid-stage clinical trials, focusing on patients with primary sclerosing cholangitis and systemic sclerosis.
